Publications

  • An in vitro model that recapitulates the epithelial to mesenchymal transition (EMT) in human breast cancer

    Katz E, Dubois-Marshall S, Sims AH, Gautier P, Meehan RR and Harrison DJ

    PLOS One 2011 (in press)

  • A gene on the HER2 amplicon, C35 (c17orf37) is an independent oncogene in breast cancer whose actions are prevented by inhibition of Syk kinase

    Katz E, Dubois-Marshall S, Sims AH, Faratian D, Smith ES, Quinn JA, Edward M, Meehan RR, Evans EE, Langdon SP, Harrison DJ

    British Journal of Cancer 2010 103:(3) : 401010

  • Discordant expression of molecular markers between primary and nodal metastases: a histopathological manifestation of the self (stem cell) seeding nature of breast cancer disease

    Faratian D, Aitken SJ, Thomas JS, Langdon SP, Harrison DJ

    Ann Oncol 2010 Mar 9

  • Dynamic changes in breast cancer gene expression in vivo predict response to tamoxifen therapy in patients with breast cancer

    Taylor K, Sims AH, Liang L, Faratian D, Muir M, Walker G, Kuske B, Dixon JM, Harrison D, Cmaeron DA, Langdon SP

    Breast Cancer Research 2010: 12(3) : R39

  • Quantitative analysis of charges in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases

    Aitken SJ, Thomas JS, Langdon SP, Harrison DJ, Faratian

    D Ann Oncol 2010 Jun 21 (6): 1254:61

  • Tyrosine phosphorylation profiling reveals the signaling network characteristics of basal breast cancer cells

    Falko Hochgrafe, Luzi Zhang, Sandra A, O'Toole, Brigid C, Browne, Mark Pinese, Ana Porta Cubas, Gillian M Lehrbach, David R Croucher, Danny Rickwood, Alice Boulghourjian, Robert Shearer, Radhika Nair, Alexander Swarbrick, Dana Faratian, Peter Mullen, David Harrison, Andrew Biankin, Robert L Sutherland, Marjk J Raftery and Roger J Daly

    Cancer Res 2010 Sept 21

  • Modulation of HER3 Is a Marker of Dynamic Cell Signaling in Ovarian Cancer: Implications for Pertuzumab Sensitivity

    Authors: Yoko Nagumo, Dana Faratian, Peter Mullen, David J. Harrison, Max Hasmann and Simon P. Langdon.

    Mol Cancer Res. 2009 Sep;7(9):1563-71.

  • Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases.

    Authors: Sarah J Aitken, Jeremy S Thomas, Simon P Langdon, David J Harrison and Dana Faratian.

    Ann Oncol 2009

  • Systems Biology Reveals New Strategies for Personalising Cancer Medicine and Confirms PTEN's Role in Resistance to Trastuzumab.

    Authors: Dana Faratian, Alexey Goltsov, Galina Lebedeva, Anatoly Sorokin, Stuart Moodie, Peter Mullen, Charlene Kay, In Hwa Um, Simon Langdon, Igor Goryanin, and David J Harrison.

    Cancer Res 2009 Jul 28

  • Systems Pathology-taking molecular pathology into a new dimension.

    Authors: Dana Faratian, Robert G Clyde, John W Crawford and David J Harrison.

    Nat Rev Clin Oncol 2009 Jul 7

  • Gonadotropin-Releasing Hormone Receptor Levels and Cell Context Q2 Affect Tumor Cell Responses to Agonist In vitro and In vivo.

    Authors: Morgan K, Stewart AJ, Miller N, Mullen P, Muir M, Dodds M, Medda F,,Harrison D Langdon S, Millar RP.

    Cancer Res 2008 Aug 1;68(15):6331-40.

  • 1